MS & Immune Disorders
News
Positive Results from Phase 2 Clinical Trials of Evobrutinib for Multiple Sclerosis
Friday, March 01, 2019—After 24 weeks of treatment, patients treated with 75 mg of evobrutinib (EMD Serono, Rockland, MA) 2 or 4 times per day had significantly fewer T1 gadolinium-enhancing (Gd+) l…
New Drug Application Novel for Oral Fumarate Accepted by Food and Drug Administration
Monday, February 25, 2019—The Food and Drug Administration (FDA) has accepted an application for diroximel fumarate (BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for the treatment of relap…
Multiple Sclerosis Prevalence May Be Twice As High as Previously Thought
Tuesday, February 19, 2019—A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925 -- more than twice the previous estimate of 400,000 pe…
Multiple Sclerosis Misdiagnosis
Alexandra Galati, MD; and Marwa Kaisey, MD
February 2019—Accurate diagnosis requires correspondence to typical clinical syndromes, correct interpretation of radiologic and CSF data, and thorough evaluation for mimics.
POINT-COUNTERPOINT: Natalizumab Extended-Interval Dosing
David B. Clifford, MD; and John F. Foley, MD
February 2019—Optimism vs caution for using extended-interval dosing to prevent progressive multifocal leukoencephalopathy.
Emerging Therapies for Progressive Multiple Sclerosis
Matthew Tremblay, MD, PhD
February 2019—A number of agents with putative neuroprotective effects have shown promise in recent clinical trials.
Maintaining Ambulation
Michelle H. Cameron, MD, PhD, MCR; and Ylva E. Nilsagård, PT, PhD
February 2019—Physical therapy, exercise, physical activity, and medications adapted to individual needs can all help maintain the ability to walk.
Immunopathogenesis of Multiple Sclerosis
Ye Hu, MD; Neeta Garg, MD; and Kottil W. Rammohan, MD
February 2019—Disruption of immune tolerance, inflammation, and blood-brain–barrier breach lead to demyelination and axonal injury.
